Peptidic GLP-1R agonists have received significant media coverage over the past year for their astounding efficacy in several indications. Whilst most of the recent fanfare has been related to their role in weight loss, they have been a mainstay of the diabetes treatment landscape for the past two decades. In addition, GLP-1R agonists have recently shown efficacy in reducing heart disease risk and treating certain chronic kidney diseases which has opened the door to potential new indications and label expansions for this drug class in the future.
00:00 Introduction
01:36 About Drug Hunter
03:50 Introduction of Dr. Oliver Philps
09:55 GLP-1 Presentation Start
52:13 Q&A
Presented by Oliver Philps, Ph.D. with host Dennis C. Koester, Ph.D. Drug Hunter.
Access additional resources and browse previous Flash Talks : drughunter.com/flashtalks/
Presented on March 14, 2024